Titre : Produits du tabac

Produits du tabac : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prothrombin Time

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment diagnostiquer une dépendance au tabac ?

Le diagnostic repose sur des questionnaires d'auto-évaluation et l'observation des symptômes de sevrage.
Dépendance au tabac Diagnostic médical
#2

Quels tests pour évaluer les effets du tabac ?

Des tests de fonction pulmonaire et des analyses de sang peuvent évaluer les effets du tabac.
Tests de fonction pulmonaire Tabagisme

Symptômes 2

#1

Quels sont les symptômes d'une intoxication au tabac ?

Les symptômes incluent nausées, vertiges, maux de tête et palpitations cardiaques.
Intoxication au tabac Symptômes
#2

Comment le tabac affecte-t-il la respiration ?

Le tabac provoque une toux chronique, un essoufflement et une diminution de la capacité pulmonaire.
Tabagisme Maladies respiratoires

Prévention 2

#1

Comment prévenir le tabagisme chez les jeunes ?

L'éducation, les campagnes de sensibilisation et les politiques anti-tabac sont essentielles.
Prévention du tabagisme Éducation à la santé
#2

Les lois anti-tabac sont-elles efficaces ?

Oui, elles réduisent la consommation de tabac et protègent les non-fumeurs de l'exposition.
Législation anti-tabac Santé publique

Traitements 2

#1

Quels traitements existent pour arrêter de fumer ?

Les traitements incluent les substituts nicotiniques, les médicaments et la thérapie comportementale.
Sevrage tabagique Traitement médicamenteux
#2

Les thérapies comportementales sont-elles efficaces ?

Oui, elles augmentent les chances d'arrêter de fumer en modifiant les comportements liés au tabagisme.
Thérapie comportementale Dépendance au tabac

Complications 2

#1

Quelles sont les complications du tabagisme ?

Les complications incluent le cancer, les maladies cardiovasculaires et les maladies respiratoires chroniques.
Complications du tabagisme Maladies cardiovasculaires
#2

Le tabac augmente-t-il le risque de cancer ?

Oui, le tabac est un facteur de risque majeur pour plusieurs types de cancer, notamment le poumon.
Cancer du poumon Tabagisme

Facteurs de risque 2

#1

Quels sont les facteurs de risque du tabagisme ?

Les facteurs incluent l'âge, l'environnement social, et l'exposition à des antécédents familiaux.
Facteurs de risque Tabagisme
#2

Le stress influence-t-il la consommation de tabac ?

Oui, le stress peut augmenter la consommation de tabac chez les individus dépendants.
Stress Dépendance au tabac
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Produits du tabac : Questions médicales les plus fréquentes", "headline": "Produits du tabac : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Produits du tabac : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-18", "dateModified": "2025-02-12", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Produits du tabac" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dispositifs pour fumer", "url": "https://questionsmedicales.fr/mesh/D000074602", "about": { "@type": "MedicalCondition", "name": "Dispositifs pour fumer", "code": { "@type": "MedicalCode", "code": "D000074602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.767" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tabac sans fumée", "alternateName": "Tobacco, Smokeless", "url": "https://questionsmedicales.fr/mesh/D014030", "about": { "@type": "MedicalCondition", "name": "Tabac sans fumée", "code": { "@type": "MedicalCode", "code": "D014030", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.767.844.500" } } }, { "@type": "MedicalWebPage", "name": "Tabac pour pipe à eau", "alternateName": "Tobacco, Waterpipe", "url": "https://questionsmedicales.fr/mesh/D000073846", "about": { "@type": "MedicalCondition", "name": "Tabac pour pipe à eau", "code": { "@type": "MedicalCode", "code": "D000073846", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.637.767.844.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Produits du tabac", "alternateName": "Tobacco Products", "code": { "@type": "MedicalCode", "code": "D062789", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Takahiro Tabuchi", "url": "https://questionsmedicales.fr/author/Takahiro%20Tabuchi", "affiliation": { "@type": "Organization", "name": "Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, Japan." } }, { "@type": "Person", "name": "Jennifer B Unger", "url": "https://questionsmedicales.fr/author/Jennifer%20B%20Unger", "affiliation": { "@type": "Organization", "name": "Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America." } }, { "@type": "Person", "name": "Pamela M Ling", "url": "https://questionsmedicales.fr/author/Pamela%20M%20Ling", "affiliation": { "@type": "Organization", "name": "Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, California." } }, { "@type": "Person", "name": "Silvano Gallus", "url": "https://questionsmedicales.fr/author/Silvano%20Gallus", "affiliation": { "@type": "Organization", "name": "Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy." } }, { "@type": "Person", "name": "Jessica L Barrington-Trimis", "url": "https://questionsmedicales.fr/author/Jessica%20L%20Barrington-Trimis", "affiliation": { "@type": "Organization", "name": "Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America. Electronic address: jtrimis@usc.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36055261", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/s-0042-1756196" } }, { "@type": "ScholarlyArticle", "name": "The prothrombin time/international normalized ratio predicts prognosis in cardiogenic shock.", "datePublished": "2023-05-01", "url": "https://questionsmedicales.fr/article/37139569", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MCA.0000000000001241" } }, { "@type": "ScholarlyArticle", "name": "Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population.", "datePublished": "2022-10-15", "url": "https://questionsmedicales.fr/article/36292752", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes13101867" } }, { "@type": "ScholarlyArticle", "name": "Association of prothrombin time, thrombin time and activated partial thromboplastin time levels with preeclampsia: a systematic review and meta-analysis.", "datePublished": "2024-05-13", "url": "https://questionsmedicales.fr/article/38741046", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-024-06543-7" } }, { "@type": "ScholarlyArticle", "name": "Data mining for prothrombin time and international normalized ratio reference intervals in children.", "datePublished": "2022-10-27", "url": "https://questionsmedicales.fr/article/36302050", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0276884" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Produits manufacturés", "item": "https://questionsmedicales.fr/mesh/D008420" }, { "@type": "ListItem", "position": 4, "name": "Dispositifs pour fumer", "item": "https://questionsmedicales.fr/mesh/D000074602" }, { "@type": "ListItem", "position": 5, "name": "Produits du tabac", "item": "https://questionsmedicales.fr/mesh/D062789" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Produits du tabac - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Produits du tabac", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Produits du tabac", "description": "Comment diagnostiquer une dépendance au tabac ?\nQuels tests pour évaluer les effets du tabac ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Prothrombin+Time#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Produits du tabac", "description": "Quels sont les symptômes d'une intoxication au tabac ?\nComment le tabac affecte-t-il la respiration ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Prothrombin+Time#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Produits du tabac", "description": "Comment prévenir le tabagisme chez les jeunes ?\nLes lois anti-tabac sont-elles efficaces ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Prothrombin+Time#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Produits du tabac", "description": "Quels traitements existent pour arrêter de fumer ?\nLes thérapies comportementales sont-elles efficaces ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Prothrombin+Time#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Produits du tabac", "description": "Quelles sont les complications du tabagisme ?\nLe tabac augmente-t-il le risque de cancer ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Prothrombin+Time#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Produits du tabac", "description": "Quels sont les facteurs de risque du tabagisme ?\nLe stress influence-t-il la consommation de tabac ?", "url": "https://questionsmedicales.fr/mesh/D062789?mesh_terms=Prothrombin+Time#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance au tabac ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des questionnaires d'auto-évaluation et l'observation des symptômes de sevrage." } }, { "@type": "Question", "name": "Quels tests pour évaluer les effets du tabac ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de fonction pulmonaire et des analyses de sang peuvent évaluer les effets du tabac." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une intoxication au tabac ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent nausées, vertiges, maux de tête et palpitations cardiaques." } }, { "@type": "Question", "name": "Comment le tabac affecte-t-il la respiration ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Le tabac provoque une toux chronique, un essoufflement et une diminution de la capacité pulmonaire." } }, { "@type": "Question", "name": "Comment prévenir le tabagisme chez les jeunes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation, les campagnes de sensibilisation et les politiques anti-tabac sont essentielles." } }, { "@type": "Question", "name": "Les lois anti-tabac sont-elles efficaces ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles réduisent la consommation de tabac et protègent les non-fumeurs de l'exposition." } }, { "@type": "Question", "name": "Quels traitements existent pour arrêter de fumer ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les substituts nicotiniques, les médicaments et la thérapie comportementale." } }, { "@type": "Question", "name": "Les thérapies comportementales sont-elles efficaces ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent les chances d'arrêter de fumer en modifiant les comportements liés au tabagisme." } }, { "@type": "Question", "name": "Quelles sont les complications du tabagisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent le cancer, les maladies cardiovasculaires et les maladies respiratoires chroniques." } }, { "@type": "Question", "name": "Le tabac augmente-t-il le risque de cancer ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabac est un facteur de risque majeur pour plusieurs types de cancer, notamment le poumon." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du tabagisme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'environnement social, et l'exposition à des antécédents familiaux." } }, { "@type": "Question", "name": "Le stress influence-t-il la consommation de tabac ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut augmenter la consommation de tabac chez les individus dépendants." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 12/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Jennifer B Unger

4 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Pamela M Ling

4 publications dans cette catégorie

Affiliations :
  • Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, California.
Publications dans "Produits du tabac" :

Silvano Gallus

3 publications dans cette catégorie

Affiliations :
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Publications dans "Produits du tabac" :

Jessica L Barrington-Trimis

3 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America. Electronic address: jtrimis@usc.edu.

Mary Ann Pentz

3 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Rob McConnell

3 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Lisa Henriksen

3 publications dans cette catégorie

Affiliations :
  • Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California, USA.
Publications dans "Produits du tabac" :

William G Shadel

3 publications dans cette catégorie

Affiliations :
  • RAND Corporation, Pittsburgh, PA, USA.

Joan S Tucker

3 publications dans cette catégorie

Affiliations :
  • RAND Corporation, Santa Monica, CA, USA.

Reinskje Talhout

3 publications dans cette catégorie

Affiliations :
  • National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Elisa Borroni

2 publications dans cette catégorie

Affiliations :
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Publications dans "Produits du tabac" :

Anna Odone

2 publications dans cette catégorie

Affiliations :
  • Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy.
  • School of Medicine, University Vita-Salute San Raffaele, 20132 Milan, Italy.
Publications dans "Produits du tabac" :

Piet A van den Brandt

2 publications dans cette catégorie

Affiliations :
  • Department of Epidemiology, CAPHRI-School for Public Health and Primary Care, Maastricht University Medical Centre, 6211 LK Maastricht, The Netherlands.
  • Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6211 LK Maastricht, The Netherlands.
Publications dans "Produits du tabac" :

Giuseppe Gorini

2 publications dans cette catégorie

Affiliations :
  • Oncologic Network, Prevention and Research Institute (ISPRO), 50139 Florence, Italy.
Publications dans "Produits du tabac" :

Alessandra Lugo

2 publications dans cette catégorie

Affiliations :
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
Publications dans "Produits du tabac" :

Satomi Odani

2 publications dans cette catégorie

Affiliations :
  • Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae Chuo-ku, Osaka, Japan.

Irfan Rahman

2 publications dans cette catégorie

Affiliations :
  • Department of Environmental Medicine, University of Rochester Medical Center, Rochester, United States.

Tess Boley Cruz

2 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Robert Urman

2 publications dans cette catégorie

Affiliations :
  • Department of Preventive Medicine, Keck School of Medicine, University of Southern California, United States of America.

Sources (10000 au total)

The prothrombin time/international normalized ratio predicts prognosis in cardiogenic shock.

The study investigates the prognostic impact of the prothrombin time/international normalized ratio (PT/INR) in patients with cardiogenic shock.... Despite ongoing improvements regarding the treatment of cardiogenic shock patients, intensive care unit (ICU)-related mortality in cardiogenic shock patients remains unacceptably high. Limited data re... All consecutive patients with cardiogenic shock from 2019 to 2021 were included at one institution. Laboratory values were collected from the day of disease onset (day 1) and days 2, 3, 4 and 8. The p... Two hundred twenty-four cardiogenic shock patients were included with a rate of all-cause mortality at 30 days of 52%. The median PT/INR on day 1 was 1.17. The PT/INR on day 1 was able to discriminate... Baseline PT/INR and an increase of the PT/INR during the course of ICU treatment were associated with the risk of 30-day all-cause mortality in cardiogenic shock patients....

Association of prothrombin time, thrombin time and activated partial thromboplastin time levels with preeclampsia: a systematic review and meta-analysis.

Preeclampsia (PE), an obstetric disorder, remains one of the leading causes of maternal and infant mortality worldwide. In individuals with PE, the coagulation-fibrinolytic system is believed to be am... This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Articles relevant to the study, published from July 26, 2013, to July 26, 2023, were systematically sea... A total of 30 articles, involving 5,964 individuals (2,883 with PE and 3,081 as normotensive pregnant mothers), were included in this study. The overall pooled SMD for PT, APTT, and TT between PE and ... The meta-analysis underscores the association between PE and prolonged PT and APTT. This suggests that evaluating coagulation parameters like PT, APTT, and TT in pregnant women could offer easily acce...

Risk stratification and prognostic value of prothrombin time and activated partial thromboplastin time among COVID-19 patients.

COVID-19 is a viral disease caused by a new strain of corona virus. Currently, prognosis and risk stratification of COVID-19 patients is done by the disease's clinical presentation. Therefore, identif... A follow-up study was conducted among conveniently recruited COVID-19 patients attended from March to June 2021. Socio-demographic and clinical data were collected using a structured questionnaire and... Baseline PT at a cut-off value ≥ 16.25 seconds differentiated severe COVID-19 patients from mild and moderate patients (AUC: 0.89, 95% CI: 0.83-0.95). PT also differentiated mild COVID-19 patients fro... Prolonged baseline PT was observed in severe COVID-19 patients. Prolonged baseline PT was also predicted to worsen prognosis. An increase from the baseline PT was associated with worsen prognosis. The...

Association between admission prothrombin time activity and hospital readmission in heart failure: A retrospective study.

Coagulopathy is a common complication of heart failure (HF), but the prognostic significance of coagulation abnormalities for HF is still poorly understood. This investigation sought to elucidate the ... In this retrospective study, we extracted data from a publicly accessible database for hospitalized HF patients in China. The admission laboratory findings were screened by the least absolute shrinkag... A total of 1505 HF patients were included, of whom 58.7% were female and 35.6% were between 70 and 79 y. In LASSO procedure, admission PTA level was included in optimized models for short-term readmis... Low admission PTA level is associated with an increased risk of 90-day and 180-day hospital readmission in patients with HF....

Patient with End-Stage Liver Disease and Prolonged Prothrombin Time Presents for Placement of a New Dental Implant.

Dentists should consult with the patient's hepatologist to obtain the most recent medical records with liver function tests and a coagulation panel. In the absence of severe liver dysfunction and with...